stockrow
Friday 6 November 2026
Export ABVX’s income statement to Excel — free account
Abivax SA Sponsored ADR
ABVX Healthcare Biotechnology
- EPS
- −98.8%
- Free cash flow
- −48.3%
- Total debt
- −98.5%
Quarter to June 2026, against a year earlier
86.19
2.01
+2.39%
Follow ABVX
Alert me
Abivax SA Sponsored ADR (ABVX) Debt to equity
Abivax SA Sponsored ADR's debt to equity at the end of the quarter to 30 June 2026 was 0.0×, down 0.0× from fiscal 2025 (0.0×). Over the past ten years it has ranged from 0.0× (fiscal 2025) to 7.3× (fiscal 2020) — the current reading is the lowest in ten years. That is above the Biotechnology industry median of 0.0× and above the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 0.0× | (99.83%) |
| FY2024 | 2.4× | 737.56% |
| FY2023 | 0.3× | (94.80%) |
| FY2022 | 5.4× | 193.28% |
| FY2021 | 1.9× | (74.46%) |
| FY2020 | 7.3× | 313.02% |
| FY2019 | 1.8× | 364.32% |
| FY2018 | 0.4× | — |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Jun 2026 | 0.0× | (2.94%) |
| Mar 2026 | 0.0× | (17.07%) |
| Dec 2025 | 0.0× | (95.43%) |
| Sep 2025 | 0.1× | — |
| 10 more quarters | Free account |
Against its own ten years
Low 0.0×
High 7.3×
Ten-year median
1.8×
Current reading's percentile
13
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| CYTK Cytokinetics, Incorporated compare | −0.5× |
| SYRE Spyre Therapeutics, Inc. compare | 0.0× |
| PRAX Praxis Precision Medicines, Inc. compare | 0.0× |
| CORT Corcept Therapeutics Incorporated compare | 0.0× |
| ORKA Oruka Therapeutics, Inc. compare | 0.0× |
| RYTM Rhythm Pharmaceuticals, Inc. compare | 0.0× |
| ABVX Abivax SA Sponsored ADR | 0.0× |
| AXSM Axsome Therapeutics, Inc. compare | 1.2× |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | 1.9× |
| Biotechnology industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)